Cargando…
Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST
PURPOSE: The development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ((223)RaCl(2)) for response assessment in osteosarcoma, NAFCIST (Na(18)F P...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435244/ https://www.ncbi.nlm.nih.gov/pubmed/30962954 http://dx.doi.org/10.1136/esmoopen-2018-000439 |
_version_ | 1783406622165434368 |
---|---|
author | Kairemo, Kalevi Rohren, Eric M Anderson, Pete M Ravizzini, Gregory Rao, Arvind Macapinlac, Homer A Subbiah, Vivek |
author_facet | Kairemo, Kalevi Rohren, Eric M Anderson, Pete M Ravizzini, Gregory Rao, Arvind Macapinlac, Homer A Subbiah, Vivek |
author_sort | Kairemo, Kalevi |
collection | PubMed |
description | PURPOSE: The development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ((223)RaCl(2)) for response assessment in osteosarcoma, NAFCIST (Na(18)F PET response Criteria in Solid Tumors). EXPERIMENTAL DESIGN: Patients received one to six cycles of (223)RaCl(2), and cumulative doses varied from 6.84 MBq to 57.81 MBq. Molecular imaging with technetium-99m phosphonate scintigraphy, fluorine-18-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET) or sodium fluoride-18 (Na(18)F) PET was used to characterise the disease. Correlation of biomarkers and survival was analysed with NAFCIST measure from Na(18)F PET. RESULTS: Of the 18 patients, 17 had bone lesions visible in at least one of the imaging studies. In four of seven patients with multiple skeletal lesions (>5), FDG PET and NaF PET studies could be compared. The skeletal tumour locations varied in our patient population: cranium=2, extremities=7, pelvis=10, spine=12 and thorax=9. The (18)F-FDG PET and Na(18)F PET studies could be compared in all four patients who had multiple lung lesions (>5). Overall the Response Evaluation Criteria in Solid Tumors response was seen in one patient, but four patients experienced mixed responses better defined by Na(18)F PET. Changes in NAFCIST were correlated with changes in bone alkaline phosphatase levels (r=0.54) and negatively with cumulative dose of (223)RaCl(2) (r=− 0.53). NAFCIST correlated with overall survival (p value of 0.037) while the PERCIST (PET Response Criteria in Solid Tumors) did not (p value of 0.19). CONCLUSIONS: Our results indicate that Na(18)F PET should be further studied in osteosarcoma staging. NAFCIST may be a promising criteria for high-risk osteosarcoma response evaluation and correlates with survival. Further validation studies are needed. |
format | Online Article Text |
id | pubmed-6435244 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-64352442019-04-08 Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST Kairemo, Kalevi Rohren, Eric M Anderson, Pete M Ravizzini, Gregory Rao, Arvind Macapinlac, Homer A Subbiah, Vivek ESMO Open Original Research PURPOSE: The development of osteosarcoma therapeutics has been challenging, in part because of the lack of appropriate criteria to evaluate responses. We developed a novel criteria in a clinical trial of radium-223 dichloride ((223)RaCl(2)) for response assessment in osteosarcoma, NAFCIST (Na(18)F PET response Criteria in Solid Tumors). EXPERIMENTAL DESIGN: Patients received one to six cycles of (223)RaCl(2), and cumulative doses varied from 6.84 MBq to 57.81 MBq. Molecular imaging with technetium-99m phosphonate scintigraphy, fluorine-18-fluorodeoxyglucose ((18)FDG) positron emission tomography (PET) or sodium fluoride-18 (Na(18)F) PET was used to characterise the disease. Correlation of biomarkers and survival was analysed with NAFCIST measure from Na(18)F PET. RESULTS: Of the 18 patients, 17 had bone lesions visible in at least one of the imaging studies. In four of seven patients with multiple skeletal lesions (>5), FDG PET and NaF PET studies could be compared. The skeletal tumour locations varied in our patient population: cranium=2, extremities=7, pelvis=10, spine=12 and thorax=9. The (18)F-FDG PET and Na(18)F PET studies could be compared in all four patients who had multiple lung lesions (>5). Overall the Response Evaluation Criteria in Solid Tumors response was seen in one patient, but four patients experienced mixed responses better defined by Na(18)F PET. Changes in NAFCIST were correlated with changes in bone alkaline phosphatase levels (r=0.54) and negatively with cumulative dose of (223)RaCl(2) (r=− 0.53). NAFCIST correlated with overall survival (p value of 0.037) while the PERCIST (PET Response Criteria in Solid Tumors) did not (p value of 0.19). CONCLUSIONS: Our results indicate that Na(18)F PET should be further studied in osteosarcoma staging. NAFCIST may be a promising criteria for high-risk osteosarcoma response evaluation and correlates with survival. Further validation studies are needed. BMJ Publishing Group 2019-02-28 /pmc/articles/PMC6435244/ /pubmed/30962954 http://dx.doi.org/10.1136/esmoopen-2018-000439 Text en © Author (s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Original Research Kairemo, Kalevi Rohren, Eric M Anderson, Pete M Ravizzini, Gregory Rao, Arvind Macapinlac, Homer A Subbiah, Vivek Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
title | Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
title_full | Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
title_fullStr | Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
title_full_unstemmed | Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
title_short | Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
title_sort | development of sodium fluoride pet response criteria for solid tumours (nafcist) in a clinical trial of radium-223 in osteosarcoma: from recist to percist to nafcist |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435244/ https://www.ncbi.nlm.nih.gov/pubmed/30962954 http://dx.doi.org/10.1136/esmoopen-2018-000439 |
work_keys_str_mv | AT kairemokalevi developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist AT rohrenericm developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist AT andersonpetem developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist AT ravizzinigregory developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist AT raoarvind developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist AT macapinlachomera developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist AT subbiahvivek developmentofsodiumfluoridepetresponsecriteriaforsolidtumoursnafcistinaclinicaltrialofradium223inosteosarcomafromrecisttopercisttonafcist |